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Abstract
In this study the construction is described of HIV-1 molecular clones in which CTL epitopes from RT or Env late
proteins were inserted into the Nef early protein. The ectopic epitopes were efficiently processed from the recombinant
Nef proteins, were recognized by their cognate CTL in cytolytic assays, and did not perturb virus replication or viral
protein expression in vitro. These recombinant viruses will therefore be an important tool in studying the effect of
distinct epitope expression kinetics on the efficiency of CTL-mediated suppression of HIV-1 replication. © 2002
Elsevier Science B.V. All rights reserved.
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HIV is a lentivirus for which protein expression
is strictly regulated during the replication cycle
(for a review, see Cullen, 1992). After entry into
the target cell, the viral proteins Tat, Rev and Nef
are the first to be expressed. The regulatory
proteins Tat and Rev are crucial for viral replica-
tion, via enhancement of transcription and regula-
tion of HIV-1 mRNA export to the cytoplasm
(Cullen, 1992; Jeang et al., 1999; Pollard and
Malim, 1998). The accessory genes encoding Vpu,
Vif and Vpr are expressed next, together with Env
Gag and Pol are the last proteins to become
detectable, after which assembly of viral particles
begins (Feinberg et al., 1986; Kim et al., 1989).
Infection with HIV leads to a chronic infection
and although the virus cannot be cleared, immu-
nity plays a role in suppressing the virus spread.
Recent reports have shown that an efficient im-
mune response against the regulatory proteins
correlates with the control of primary viremia
(Allen et al., 2000) and chronic infection (Geretti
et al., 1999) in SIV-infected monkeys, and with a
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better prognosis for HIV-1 infected individuals
(van Baalen et al., 1997; Zagury et al., 1998). This
is substantiated further by a recent study, which
showed no significant differences between the con-
trol of viremia in infected individuals and the
presence of CTL responses against Tat and Rev,
but demonstrated that the breadth of the CTL
response against Tat correlates with an efficient
control of disease progression (Addo et al., 2001).
To test whether the early expression of Tat and
Rev contributes to the more effective control of
HIV/SIV viremia it was decided to manipulate the
expression kinetics of CTL epitopes. Deletion,
insertion or mutation in the tat and re genes is
problematic, because the open reading frames
(ORFs) partially overlap with each other and with
en (Myers et al., 1998). In contrast, the early
expressed nef gene does not overlap with other
ORFs (Myers et al., 1998). Moreover, although
Nef-deleted HIV-1 variants display a lower patho-
genicity in vivo, they are replication-competent in
vitro (Harris, 1996), which makes the nef gene a
more suitable candidate for genetic modifications.
The construction of full length, infectious HIV-
1 molecular clones is described, in which CTL
epitopes from the late HIV-1 proteins RT and
Env have been inserted in frame into the nef
ORF. The molecular clone pACH320.2A.2.1
(HIV-12.1WT), which has been described previously
(Groenink et al., 1991; Guillon et al., 1995), was
subcloned in two halves named pXE2.1 and
pEX2.1, respectively (Guillon et al., 1997). DNA
was amplified using Escherichia coli STBL2
(Gibco-BRL), grown at 30 °C to avoid recombi-
nation (Joshi and Jeang, 1993), and purified on
cesium chloride gradients using standard methods
(Sambrook et al., 1989). We inserted ectopic epi-
topes in the unique Bpu1102I site (position 67–73
in the nef gene), which was located close to a
natural CTL epitope of Nef, providing a fa-
vourable context for antigen processing (Korber
et al., 1999). pEX2.1 subclones were digested with
Bpu1102I (MBI Fermentas), dephosphorylated
using Calf Intestine Phosphatase (Boehringer–
Mannheim), and purified on agarose gels (DNA
extraction kit, Boehringer–Mannheim). The nu-
cleotide sequences encoding the Env589–597
(ERYLKDQQL) and RT244–252 (IVLPEKDSW)
CTL epitopes, which are recognised in the context
of HLA-B14 and -B57, respectively (Johnson et
al., 1992; Klein et al., 1998), were generated by
annealing complementary oligonucleotides (Fig.
1A). These sequences were ligated into pEX2.1 to
create pEX2.1EN and pEX2.1RN, respectively.
Clones were sequenced to confirm the correct
presence of the epitopes. To generate the
pEX2.1NM constructs, subclones were digested
with Xho I (position 101–106 in the nef gene) and
incubated with Kleenow DNA polymerase (New
England Biolabs) in the presence of 30 mM
dNTPs. This resulted in a frame shift after amino
acid 35 and a truncated Nef protein of 56 amino
acids (Fig. 1C). pEX2.1EN, pEX2.1RN and
pEX2.1-NM were cloned back into full-length
pACH320.2A.2.1 (Fig. 1B) and transfected into
293-T cells for the production of infectious HIV-
12.1EN, HIV-12.1RN, HIV-12.1NM and HIV-12.1WT
stocks, as described previously (Pear et al., 1993).
The replication characteristics of these recombi-
nant viruses were evaluated using TCL2H7 cells, a
non-transformed CD4+ T cell line supporting
replication of primary HIV isolates and present-
ing HLA B14- and B57-restricted epitopes (van
Baalen et al., 1998). The cells require re-stimula-
tion every 14 days using PHA-L (1 g/ml) and
gamma-irradiated feeder cells, and susceptibility
to HIV infection was optimal at day 3 after
stimulation (van Baalen et al., 1998). Therefore,
virus replication could be monitored for 10 days,
without the need for re-stimulation or adding
freshly stimulated cells. Cells were incubated with
2-, 20- and 200-fold dilutions of the transfection
supernatants for 90 min, and washed subse-
quently twice to remove unbound virions. Cul-
tures were initiated with 3×105 cells, and virus
production in the supernatant was measured using
a double sandwich p24 ELISA (Cheynet et al.,
1993; Guillon et al., 1997). In parallel, 5-fold
dilutions of the cells inoculated with the highest
virus concentration were cultured in quadrupli-
cate with uninfected TCL2H7 cells for 2 weeks,
and the number of positive wells for each of the
cell dilutions was used to estimate the initial frac-
tion of infected cells. At the start, cultures in-
fected with HIV-12.1WT, HIV-12.1EN, HIV-12.1RN or
HIV-12.1NM contained a number of infected cells
C
.
G
uillon
et
al./
Journal
of
V
irological
M
ethods
99
(2002)
115
–
121
117
Fig. 1. Generation of the artificial epitopes. (A) Description of the oligonucleotides depicted as annealing product. The DNA strands coding for the epitopes are shown
in bold. (B) Recombinant full-length HIV-1 molecular clones generated in this study. The ectopic epitopes are depicted as grey and striped areas at their respective
natural position and in the recombinant nef gene for the p2.1EN and p2.1RN constructs. (C) Aminoacid sequence of the p2.1NM Nef protein. Residues in italic are
the result of the frameshift in the nef ORF.
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proportional to 418, 187, 17 and 125 ID50 per
3×105 cells, respectively. As shown in Fig. 2, the
insertions into or truncation of Nef did not affect
in vitro replication kinetics in TCL2H7 cells. At
the peak of virus production, p24 concentrations
in the supernatant were similar for all infections,
between 500 and 1000 ng/ml. Similar results were
observed when viruses were used to infect PHA-
stimulated PBMCs (data not shown). The inserts
and the truncation were stable, since the nef genes
of virus isolated at the end of the observation
period were identical to the nef genes of the input
virus (data not shown). The differences in growth
kinetics correlated with the differences in the esti-
mated initial fraction of infected cells. Tenfold
dilutions of the inoculum resulted in a 1–2-day
delay in peak virus production, as was shown
previously by Dimitrov et al. (1993).
Infected cells were lysed at the peak of p24
replication to assess Nef and Gag expression from
the recombinant viruses by Western blot using
Nef-specific monoclonal antibodies EVA3068.1
and EVA3067.5 clone 3A2 (Ovod et al., 1992) or
with p24-specific antibody 14D4E11 (Janvier et
al., 1990). As shown in Fig. 3, upper panel, Nef
expression was detected in HIV-12.1EN and HIV-
12.1RN infected cells. Nef proteins containing the
ectopic epitopes (Fig. 3, lanes 2 and 3) showed a
slightly higher apparent molecular weight than the
wild-type Nef (Fig. 3, lane 1), but all proteins had
a molecular weight around the expected size of 32
kD. Thus, the insertion of Env- or RT-specific
epitopes in the nef ORF of the full-length
ACH320.2A.2.1 molecular clone did not perturb
viral replication or Nef expression. Nef could not
be detected in cells infected with the Nef-trun-
cated HIV-12.1NM virus (Fig. 3, lane 4), but Gag
proteins were detected by Western blots on the
same lysate (Fig. 3, lower panel), indicating that
viral proteins were expressed normally, despite the
lack of Nef expression of HIV-12.1NM.
To assess whether the ectopic epitopes could be
processed and presented from the Nef protein, we
constructed recombinant vaccinia viruses (rVV)
for the expression of the recombinant Nef
proteins. The nef genes were amplified from the
pEX2.1EN or pEX2.1RN plasmid, with primers
5Nef-SalI (5-GTCGACGGGGATGGGTG-
GCAAGTGGTCAAA-3) and 3Nef-EcoRI (5-
GAATTCTTAGCAGTCCTTGTAGTACTCCG-3
), where restriction sites are underlined. The full-
length nef ORFs were then cloned into the
pTG186.poly plasmid (Kieny et al., 1986) using
the SalI and EcoRI restriction sites. Recombinant
vaccinia viruses were generated by homologous
recombination and TK-selection as described
(Kieny et al., 1986). Plaque purified rVV clones
containing the correct nef gene and showing Nef
expression, rVV2.1EN and rVV2.1RN, were selected
by sequence analyses and Western blots (data not
Fig. 2. Kinetics of viral replication in TCL2H7 cells. Levels of p24 were measured in supernatants of cell cultures infected with 2-,
20-, or 200-fold dilutions of HIV-12.1WT, HIV-12.1EN, HIV-12.1RN or HIV-12.1NM virus stocks.
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Fig. 3. Nef expression from recombinant HIV-1 viruses in
PBMC. Crude cell lysates of HIV-12.1WT, HIV-12.1EN, HIV-
12.1RN, HIV-12.1NM-infected PBMC were analysed in Western
blot with (upper panel) Nef-specific monoclonal antibodies
EVA3068.1 and EVA3067.5 clone 3A2 (Ovod et al., 1992) or
(lower panel) with p24-specific antibody 14D4E11 (Janvier et
al., 1990). Lane 1, HIV-12.1WT; lane 2, HIV-12.1EN; lane 3,
HIV-12.1RN; and lane 4, HIV-12.1NM.
from the recombinant Nef gene and recognised by
their specific CTLs.
RT and Env epitopes were inserted in a region
of Nef located 4 residues downstream of the
C-terminal end of a naturally processed Nef CTL
epitope. In line with previous reports which ad-
dressed the insertion of CTL epitopes in het-
erologous proteins (Beekman et al., 2000; Weidt
et al., 1995), the antigenic inserts from our con-
structs were presented efficiently to CTL in a
MHC class I restricted manner. One cannot ex-
clude that the heterologous context of the ectopic
epitopes might have influenced epitope processing
from the EpiNef constructs, either in size of the
generated peptides or in the protease pathway
involved (Del Val et al., 1991; Niedermann et al.,
1999). However, the influence of the site of inser-
tion on epitope processing in our system has to be
limited since rVV infected target cells were very
efficiently lysed. The insertion of epitopes in Nef
did not impair viral replication kinetics, even
when the infection was performed at a low MOI,
suggesting the recombination did not perturb the
natural function of Nef in the replication cycle
(Chowers et al., 1994). However, the insertion site
Fig. 4. Recognition of ectopic epitopes by their specific CTL.
Percent specific lysis of BLCL709 cells infected with rVV2.1EN
or rVV2.1RN, or pulsed with peptides corresponding to the
minimal epitopes, by Env- or RT-specific CTL. Means of
triplicates with standard error are shown.
shown). The B-lymphoblastoid cell line BLCL709
(HLA B14, B57) was infected with rVV2.1EN or
rVV2.1RN and after o/n incubation cocultured at a
1:10 ratio in a standard 4 h chromium-release
assay (van Baalen et al., 1998), using Env-specific
CTL clone KMTCC4-1280 (CD8+, HLA-B14-re-
stricted, ERYLDQQL-specific, which is similar to
a previously described clone (Johnson et al.,
1992)) or RT-specific CTL clone 090TCL1C11
(CD8+, HLA-B57-restricted, IVLPEKDSW-spe-
cific (Klein et al., 1998)). As a control, the
BLCL709 cells were pulsed with 10 M of the
minimal Env or RT epitope peptide. As shown in
Fig. 4, target cells infected by rVV2.1EN or
rVV2.1RN were only lysed efficiently by the CTL
specific for the inserted epitope. The level of lysis
was comparable or higher for rVV-infected cells
than for cells pulsed with the minimal epitope
peptides (Fig. 4). This showed that the Env and
RT-ectopic epitopes were efficiently processed
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is located close to a domain involved in the ability
of Nef to modulate expression of class I MHC
molecules (Collins et al., 1998; Piguet and Trono,
1999), and additional experiments are therefore
needed to assess the effect of the insertions in Nef
on this mechanism.
In this study, CTL epitopes from the structural
HIV-1 proteins Env or RT were inserted in the early
expressed Nef ORF of HIV-1. These insertions
were not deleterious for HIV-1 replication in vitro,
and did not perturb Nef expression. In addition, the
inserted CTL epitopes were processed and effi-
ciently recognised by specific CTL despite their
ectopic position. Moreover, this system uses a
primary HIV-1 isolate and a primary, non-immor-
talized, CD4-positive T-cell clone to be as close as
possible from the in vivo situation. These recombi-
nant viruses have since been used successfully to
demonstrate the effect of distinct epitope expres-
sion kinetics on the ability of CTL to inhibit HIV
replication (van Baalen et al., submitted for publi-
cation), and could provide new insights in the
mechanisms underlying the control of HIV-1 repli-
cation by the immune system in vivo.
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